LEXX Lexaria Bioscience Corp.

Nasdaq www.lexariabioscience.com


$ 0.84 $ -0.03 (-2.96 %)    

Wednesday, 15-Oct-2025 15:59:54 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 0.8481
$ 0.88
$ 0.83 x 10,000
$ 0.95 x 100
$ 0.84 - $ 0.90
$ 0.77 - $ 3.05
231,835
na
16.59M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-14-2025 05-31-2025 10-Q
2 04-14-2025 02-28-2025 10-Q
3 01-10-2025 11-30-2024 10-Q
4 11-26-2024 08-31-2024 10-K
5 07-12-2024 05-31-2024 10-Q
6 04-09-2024 02-29-2024 10-Q
7 01-12-2024 11-30-2023 10-Q
8 11-20-2023 08-31-2023 10-K
9 07-14-2023 05-31-2023 10-Q
10 04-14-2023 02-28-2023 10-Q
11 01-17-2023 11-30-2022 10-Q
12 11-28-2022 08-31-2022 10-K
13 07-14-2022 05-31-2022 10-Q
14 04-11-2022 02-28-2022 10-Q
15 01-14-2022 11-30-2021 10-Q
16 11-27-2021 08-31-2021 10-K
17 07-15-2021 05-31-2021 10-Q
18 04-14-2021 02-28-2021 10-Q
19 01-14-2021 11-30-2020 10-Q
20 10-15-2020 08-31-2020 10-K
21 06-30-2020 05-31-2020 10-Q
22 04-03-2020 02-29-2020 10-Q
23 01-09-2020 11-30-2019 10-Q
24 11-14-2019 08-31-2019 10-K
25 07-08-2019 05-31-2019 10-Q
26 04-15-2019 02-28-2019 10-Q
27 01-11-2019 11-30-2018 10-Q
28 11-14-2018 08-31-2018 10-K
29 07-13-2018 05-31-2018 10-Q
30 04-12-2018 02-28-2018 10-Q
31 01-12-2018 11-30-2017 10-Q
32 11-27-2017 08-31-2017 10-K
33 07-14-2017 05-31-2017 10-Q
34 04-14-2017 02-28-2017 10-Q
35 01-13-2017 11-30-2016 10-Q
36 11-29-2016 08-31-2016 10-K
37 07-13-2016 05-31-2016 10-Q
38 04-13-2016 02-29-2016 10-Q
39 01-08-2016 11-30-2015 10-Q
40 11-27-2015 08-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lexaria-awarded-4-new-patents-covering-therapeutics-for-diabetes-hypertension-seizure-disorders-and-antiviral-treatments

Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intelle...

 nasdaq-gains-100-points-us-consumer-sentiment-falls

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow ...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 dow-jumps-over-250-points-feds-key-inflation-gauge-remains-hot

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Friday. The Dow traded up 0...

 lexaria-bioscience-prices-4m-registered-direct-offering-at-150share-with-137-warrants-in-concurrent-private-placement

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a global innovator in drug delive...

 why-top-kingwin-shares-are-trading-higher-by-87-here-are-20-stocks-moving-premarket

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales ...

 why-are-lexaria-bioscience-shares-soaring-45-after-hours

Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a dramatic 45.10% surge in after-hours trading on Thursday, climbing to $2....

 effective-september-19-2025-lexaria-bioscience-terminated-the-capital-on-demand-sales-agreement-with-jonestrading-institutional-services

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001348362/000164033425001717/lxrp_8k.htm

Core News & Articles

Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NA...

Core News & Articles

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

 watching-lexaria-bioscience-zacks-small-cap-research-gives-stock-8-price-valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf

 hc-wainwright--co-maintains-buy-on-lexaria-bioscience-lowers-price-target-to-4

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target fr...

Core News & Articles

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastroint...

Core News & Articles

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted sid...

 lexaria-bioscience-q3-eps-021-misses-016-estimate-sales-174000k-beat-91333k-estimate

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-lexaria-bioscience-lowers-price-target-to-5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target fr...

Core News & Articles

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotineKELOWNA, BC / ACCESS Newswire / J...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION